 |
|
Striatal Dopamine Transporter Binding Assessed by [I-123]IPT and Single Photon Emission Computed Tomography in Patients With Early Parkinson's Disease
Implications for a Preclinical Diagnosis
Johannes Schwarz, MD;
Rainer Linke, MD;
Martina Kerner, MD;
P. David Mozley, PhD;
Claudia Trenkwalder, MD;
Thomas Gasser, MD;
Klaus Tatsch, MD
Arch Neurol. 2000;57:205-208.
Background Specific binding to dopamine transporters may serve as a tool to detect early loss of nigrostriatal dopaminergic neurons in patients with Parkinson's disease.
Objective To determine striatal dopamine transporter binding using the cocaine analogue [I-123]N-(3-iodopropen-2-yl)-2 -carbomethoxy-3-(4-chlorophenyl) tropane ([I-123]IPT) and single photon emission computed tomography.
Patients and Methods We studied 9 control subjects (mean age, 58 years; range, 41-69 years) and 28 patients with early Parkinson's disease (Hoehn and Yahr stages I [n = 14] and II [n = 14] [symptom duration, <5 years]; mean age, 55.5 years; range, 36-71 years). Single photon emission computed tomography was performed 90 minutes after injection of 120 to 150 MBq of radioactive [I-123]IPT.
Results Specific striatal [I-123]IPT binding (mean ± SD) was significantly reduced in patients with early Parkinson's disease (ipsilateral striatum: 4.09 ± 0.97; range, 2.46-6.40; contralateral striatum: 3.32 ± 0.76; range, 1.80-5.13) compared with controls (left striatum: 7.28 ± 0.94; range, 5.78-8.81; right striatum: 7.41 ± 1.28; range, 5.58-9.44). IPT binding ratios (mean ± SD) were significantly lower in patients with Hoehn and Yahr stage II (ipsilateral striatum: 3.47 ± 0.75; contralateral striatum: 2.96 ± 0.73) compared with those with Hoehn and Yahr stage I (ipsilateral striatum: 4.72 ± 0.75; contralateral striatum: 3.69 ± 0.61) (P<.001). The ipsilateral striatum of patients with Hoehn and Yahr stage I showed a significant mean ± SD reduction of IPT binding (ipsilateral striatum: 4.72 ± 0.75) compared with either right or left striatum of controls (P<.001). Only in 1 patient was IPT binding to the ipsilateral striatum (ratio, 6.40) higher than the lowest value observed in the striatum of a control subject (ratio, 5.58).
Conclusions Use of [I-123]IPT and single photon emission computed tomography demonstrates a reduction of dopamine transporter binding in patients with early Parkinson's disease. Significantly reduced IPT binding already observed in the ipsilateral striatum of patients with Hoehn and Yahr stage I demonstrates the potential of this method to detect preclinical disease.
From the Department of Neurology, University of Ulm, Ulm, Germany (Dr Schwarz); the Departments of Nuclear Medicine (Drs Linke, Kerner, and Tatsch) and Neurology (Dr Gasser), Ludwig-Maximilians-University of Munich, Munich, Germany; the Departments of Radiology and Psychiatry, University of Pennsylvania (Dr Mozley); and the Max-Planck-Institute of Psychiatry, Clinical Institute, Neurology, Munich (Dr Trenkwalder). Dr Schwarz is now with the Division of Biology, California Institute of Technology, Pasadena.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 2000;57(2):284-285.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Pharmacological Characterization of (E)-N-(4-Fluorobut-2-enyl)-2beta-carbomethoxy-3beta-(4'-tolyl)nortropane (LBT-999) as a Highly Promising Fluorinated Ligand for the Dopamine Transporter
Chalon et al.
J. Pharmacol. Exp. Ther. 2006;317:147-152.
ABSTRACT
| FULL TEXT
Biomarkers and Parkinson's disease
Michell et al.
Brain 2004;127:1693-1705.
ABSTRACT
| FULL TEXT
Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder: Comparison with Parkinson's disease and controls
Eisensehr et al.
Brain 2000;123:1155-1160.
ABSTRACT
| FULL TEXT
|
